Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
    • Publication Information:
      Original Publication: Ann Arbor, Michigan : American Society for Clinical Investigation, [2016]-
    • Subject Terms:
      Mutation*; Biomarkers/*analysis ; DNA, Viral/*genetics ; Hepatitis B/*complications ; Hepatitis B Surface Antigens/*genetics ; Hepatitis B virus/*genetics ; Liver Cirrhosis/*epidemiology; Adult ; DNA, Viral/analysis ; Europe/epidemiology ; Female ; Genotype ; Hepatitis B/genetics ; Hepatitis B/virology ; Hepatitis B virus/isolation & purification ; Heterozygote ; Humans ; Liver Cirrhosis/diagnosis ; Liver Cirrhosis/virology ; Male ; Middle Aged ; Promoter Regions, Genetic
    • Abstract:
      Many mutation analyses of the HBV genome have been performed in the search for new prognostic markers. However, the Kozak sequence preceding precore was covered only infrequently in these analyses. In this study, the HBV core promoter/precore region was sequenced in serum samples from European inactive HBV carriers. Quadruple mutation GCAC1809-1812TTCT was found with a high prevalence of 42% in the Kozak sequence preceding precore among all HBV genotypes. GCAC1809-1812TTCT was strongly associated with coexistence of basal core promoter (BCP) double mutation A1762T/G1764A and lower HBV DNA levels. In vitro GCAC1809-1812TTCT lead to drastically diminished synthesis of pregenomic RNA (pgRNA), precore mRNA, core, HBsAg, and HBeAg. Calculation of the pgRNA secondary structure suggests a destabilization of the pgRNA structure by A1762T/G1764A that was compensated by GCAC1809-1812TTCT. In 125 patients with HBV-related cirrhosis, GCAC1809-1812TTCT was not detected. While a strong association of GCAC1809-1812TTCT with inactive carrier status was observed, BCP double mutation was strongly correlated with cirrhosis, but this was only observed in absence of GCAC1809-1812TTCT. In conclusion, our data reveal that GCAC1809-1812TTCT is highly prevalent in inactive carriers and acts as a compensatory mutation for BCP double mutation. GCAC1809-1812TTCT seems to be a biomarker of good prognosis in HBV infection.
    • References:
      J Virol. 1996 Sep;70(9):5845-51. (PMID: 8709203)
      Gastroenterology. 2006 Mar;130(3):678-86. (PMID: 16530509)
      Hepatology. 2016 Jan;63(1):261-83. (PMID: 26566064)
      J Virol. 1995 Sep;69(9):5437-44. (PMID: 7636989)
      J Virol. 1998 Aug;72(8):6785-95. (PMID: 9658127)
      J Virol. 2003 Jun;77(12):6601-12. (PMID: 12767980)
      Gastroenterology. 2003 Nov;125(5):1370-8. (PMID: 14598253)
      J Virol. 2002 Dec;76(24):13001-14. (PMID: 12438626)
      Liver Int. 2009 Jan;29 Suppl 1:100-7. (PMID: 19207972)
      J Hepatol. 2016 Apr;64(1 Suppl):S4-S16. (PMID: 27084035)
      Gastroenterology. 2019 Dec;157(6):1518-1529.e3. (PMID: 31470004)
      Gastroenterology. 2010 Aug;139(2):483-90. (PMID: 20451520)
      PLoS One. 2018 Feb 6;13(2):e0191970. (PMID: 29408943)
      Hepatol Int. 2016 Jan;10(1):1-98. (PMID: 26563120)
      Hepatology. 1999 Mar;29(3):946-53. (PMID: 10051502)
      Virology. 1996 Dec 15;226(2):269-80. (PMID: 8955047)
      Hepatology. 1998 Nov;28(5):1390-7. (PMID: 9794926)
      Gut. 2015 Feb;64(2):292-302. (PMID: 24763132)
      J Gen Virol. 2008 Apr;89(Pt 4):901-909. (PMID: 18343830)
      Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W70-4. (PMID: 18424795)
      J Hepatol. 2017 Feb;66(2):398-411. (PMID: 27575311)
      J Infect Dis. 2018 Jun 5;218(1):114-123. (PMID: 29528436)
      J Gen Virol. 1998 Feb;79 ( Pt 2):375-80. (PMID: 9472623)
      Aliment Pharmacol Ther. 2018 Jun;47(11):1523-1535. (PMID: 29637585)
      Hepatology. 2005 Dec;42(6):1300-9. (PMID: 16317706)
      Hepatology. 2016 Aug;64(2):381-9. (PMID: 27079545)
      JAMA. 2006 Jan 4;295(1):65-73. (PMID: 16391218)
      J Infect Dis. 2008 Dec 1;198(11):1634-42. (PMID: 18939932)
      Life Sci Alliance. 2019 Mar 27;2(2):. (PMID: 30918010)
      Nucleic Acids Res. 1996 Sep 1;24(17):3295-301. (PMID: 8811080)
      J Hepatol. 2015 Apr;62(4):791-8. (PMID: 25445396)
      Hepatology. 2001 Jan;33(1):277-86. (PMID: 11124846)
      J Hepatol. 2017 Aug;67(2):370-398. (PMID: 28427875)
      Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3575-80. (PMID: 14990795)
      Sci Transl Med. 2017 Sep 27;9(409):. (PMID: 28954926)
      World J Gastroenterol. 2014 Jan 14;20(2):425-35. (PMID: 24574711)
      Gastroenterology. 1995 Nov;109(5):1618-23. (PMID: 7557146)
      Gastroenterology. 2003 Feb;124(2):327-34. (PMID: 12557138)
    • Contributed Indexing:
      Keywords: Clinical practice; Hepatology; Molecular biology; Virology
    • Accession Number:
      0 (Biomarkers)
      0 (DNA, Viral)
      0 (Hepatitis B Surface Antigens)
    • Publication Date:
      Date Created: 20201015 Date Completed: 20210607 Latest Revision: 20210607
    • Publication Date:
      20231215
    • Accession Number:
      PMC7710305
    • Accession Number:
      10.1172/jci.insight.135833
    • Accession Number:
      33055418